Full version of CIA-I exam files provided at killexams.com

All of us have been performing great find this difficult to offer you actual Certified Internal Auditor (CIA) examination questions and solutions, along with details. Each CIA-I question upon killexams.com offers has been certified simply by Financial certified specialists. These people are exceptionally certified and certified individuals, who have many times of specialist experience identified along with the CIA-I exam. Learning our CIA-I pdf download is enough to pass CIA-I examination with high represents.

Exam Code: CIA-I Practice exam 2022 by Killexams.com team
CIA-I Certified Internal Auditor (CIA)

Part 1 – Essentials of Internal Auditing
125 questions I 2.5 hours (150 minutes)

The CIA exam Part 1 is well aligned with The IIAs International Professional Practices Framework (IPPF) and includes six domains covering the foundation of internal auditing; independence and objectivity; proficiency and due professional care; quality assurance and improvement programs; governance, risk management, and control; and fraud risk. Part one tests candidates knowledge, skills, and abilities related to the International Standards for the Professional Practice of Internal Auditing, particularly the Attribute Standards (series 1000, 1100, 1200, and 1300) as well as Performance Standard 2100.

Part 2 – Practice of Internal Auditing
100 questions I 2.0 hours (120 minutes)

The CIA exam Part 2 includes four domains focused on managing the internal audit activity, planning the engagement, performing the engagement, and communicating engagement results and monitoring progress. Part 2 tests candidates knowledge, skills, and abilities particularly related to Performance Standards (series 2000, 2200, 2300, 2400, 2500, and 2600) and current internal audit practices.

Part 3 – Business Knowledge for Internal Auditing
100 questions I 2.0 hours (120 minutes)

The CIA exam Part 3 includes four domains focused on business acumen, information security, information technology, and financial management. Part Three is designed to test candidates knowledge, skills, and abilities particularly as they relate to these core business concepts.

CIA exam Development and Scoring
The CIA exam is developed following best practices with the support of experts and professionals. Learn more about the exam development process and how exams are scored.

The revised CIA exam Part 1 is well aligned with The IIAs International Professional Practices Framework (IPPF) and includes six domains covering the foundation of internal auditing; independence and objectivity; proficiency and due professional care; quality assurance and improvement programs; governance, risk management, and control; and fraud risk. Part One tests candidates knowledge, skills, and abilities related to the International Standards for the Professional Practice of Internal Auditing, particularly the Attribute Standards (series 1000, 1100, 1200, and 1300) as well as Performance Standard 2100.​
Domains Collapse All
I. Foundations of Internal Auditing (15%)
​ ​ ​Cognitive Level
A​ ​​Interpret The IIA's Mission of Internal Audit, Definition of Internal Auditing, and Core Principles for the Professional Practice of Internal Auditing, and the purpose, authority, and responsibility of the internal audit activity Proficient
​B ​Explain the requirements of an internal audit charter (required components, board approval, communication of the charter, etc.) Basic
​C ​Interpret the difference between assurance and consulting services provided by the internal audit activity ​Proficient
​D ​Demonstrate conformance with the IIA Code of Ethics ​​Proficient
II. ​Independence and Objectivity (15%)
​ ​ ​Cognitive Level
A​ ​​Interpret organizational independence of the internal audit activity (importance of independence, functional reporting, etc.) Basic
​B ​Identify whether the internal audit activity has any impairments to its independence Basic
​C ​Assess and maintain an individual internal auditor's objectivity, including determining whether an individual internal auditor has any impairments to his/her objectivity ​Proficient
​D ​Analyze policies that promote objectivity ​​Proficient
III. Proficiency and Due Professional Care (18%)​
​ ​ ​Cognitive Level
A​ ​​Recognize the knowledge, skills, and competencies required (whether developed or procured) to fulfill the responsibilities of the internal audit activity Basic
​B ​Demonstrate the knowledge and competencies that an internal auditor needs to possess to perform his/her individual responsibilities, including technical skills and soft skills (communication skills, critical thinking, persuasion/negotiation and collaboration skills, etc.) Proficient
​C Demonstrate due professional care ​Proficient
​D Demonstrate an individual internal auditor's competency through continuing professional development ​​Proficient
IV. Quality Assurance and Improvement Program (7%)​
​ ​ ​Cognitive Level
A​ ​​Describe the required elements of the quality assurance and improvement program (internal assessments, external assessments, etc.) Basic
​B ​Describe the requirement of reporting the results of the quality assurance and improvement program to the board or other governing body Basic
​C ​​Identify appropriate disclosure of conformance vs. nonconformance with The IIAs International Standards for the Professional Practice of Internal Auditing Basic
V. Governance, Risk Management, and Control (35%)
​ ​ ​Cognitive Level
A​ ​​Describe the concept of organizational governance Basic
​B ​Recognize the impact of organizational culture on the overall control environment and individual engagement risks and controls Basic
​C ​Recognize and interpret the organization's ethics and compliance-related issues, alleged violations, and dispositions ​Basic
​D ​Describe corporate social responsibility ​​Basic
​E ​Interpret fundamental concepts of risk and the risk management process Proficient​
​F ​Describe globally accepted risk management frameworks appropriate to the organization (COSO - ERM, ISO 31000, etc.) Basic​
G​ ​Examine the effectiveness of risk management within processes and functions ​Proficient
​H ​Recognize the appropriateness of the internal audit activitys role in the organization's risk management process ​Basic
​I ​Interpret internal control concepts and types of controls ​Proficient
​J ​Apply globally accepted internal control frameworks appropriate to the organization (COSO, etc.) ​Proficient
​K ​Examine the effectiveness and efficiency of internal controls Proficient​
VI. Fraud Risks (10%)​
​ ​ ​Cognitive Level
A​ ​​Interpret fraud risks and types of frauds and determine whether fraud risks require special consideration when conducting an engagement Proficient
​B ​Evaluate the potential for occurrence of fraud (red flags, etc.) and how the organization detects and manages fraud risks Proficient
​C ​Recommend controls to prevent and detect fraud and education to Boost the organization's fraud awareness ​Proficient
​D ​Recognize techniques and internal audit roles related to forensic auditing (interview, investigation, testing, etc.) ​​Basic
Additional noteworthy elements related to the revised CIA Part One exam syllabus:

IPPF elements such as the Mission of Internal Audit and Core Principles for the Professional Practice of Internal Auditing are included.
The syllabus features greater alignment with The IIAs Attribute Standards.
The exam covers the differences between assurance and consulting engagements.
The exam covers appropriate disclosure of conformance vs. nonconformance with the Standards.
The largest domain is “Governance, Risk Management, and Control,” which makes up 35%of the exam.
A portion of the exam requires candidates to demonstrate a basic comprehension of concepts; another portion requires candidates to demonstrate proficiency in their knowledge, skills, and abilities.

The Certified Internal Auditor® (CIA®) exam is developed following best practices with the support of experts and professionals. In accordance with exam development industry standards, a job analysis study is conducted with a diverse and experienced group of internal auditors to identify the essential knowledge and skills required for internal auditors.
This information is then distributed more broadly to the field through an online survey to obtain additional feedback from internal auditors around the world, to validate its importance and ensure that it reflects current internal audit practices.
Based on the results of the global job analysis study, the CIA exam syllabus is developed. The exam syllabus guides the development of exam questions to ensure the fairness and validity of the exam.

Certified Internal Auditor (CIA)
Financial Certified testing
Killexams : Financial Certified testing - BingNews https://killexams.com/pass4sure/exam-detail/CIA-I Search results Killexams : Financial Certified testing - BingNews https://killexams.com/pass4sure/exam-detail/CIA-I https://killexams.com/exam_list/Financial Killexams : CFA vs. CFP: The Difference Explained No result found, try new keyword!This is a 170 multiple-choice question test taken in two three-hour sessions ... The CAIA is a global certification for financial professionals who manage, analyze, sell or regulate alternative ... Mon, 11 Jul 2022 02:15:00 -0500 text/html https://money.usnews.com/investing/investing-101/articles/cfa-vs-cfp-what-they-are-and-how-they-differ Killexams : Population Genetic Testing: Save Lives And Money, While Avoiding Financial Toxicity

Genetic testing once was offered only to people with rare genetic conditions, or strong family histories of disease that spanned generations. But genetic testing is now being offered to healthy people, to detect if they carry a genetic change (often referred to as a “variant” or “mutation”) that may place them at high risk to develop preventable conditions, including some cancers and cardiac conditions.

In theory, population genetic testing makes sense. Instead of waiting for a person to die of a heart attack at a young age, we can learn of some of those risks ahead of time and mitigate them. This approach works not only for the person having testing and their family members – who may also be at risk – but also for our medical system, employers, and overarching health care costs that we, as a society, want to minimize.

But in practice, are we there yet? Cristi’s story illustrates that we still have a long way to go to make population genetic testing a win for the patient and their family members. Cristi is a certified genetic counselor who, like many of us, knew that several members of her family had developed cancer. But the cancers in Cristi’s family did not fit into a known hereditary cancer syndrome. Cristi’s mom had genetic testing based on her personal history of a brain tumor and melanoma, and family history of breast and prostate cancer, and no mutations were found in her DNA. So when Cristi signed up for genetic testing to check the customer experience of a population-based screening program offered by her company, she was surprised to learn that she carried a pathogenic variant in a gene called RET.

People who carry a RET variant have a syndrome called Multiple Endocrine Neoplasia 2A (MEN2A) and are considered to have an almost 100% chance of developing an aggressive type of thyroid cancer called medullary thyroid cancer. For this reason, people with MEN2A have traditionally been counseled to remove their thyroid gland preventively, often in childhood, before they develop cancer. MEN2A is also associated with a high risk of developing pheochromocytomas (tumors on the adrenal glands) and tumors of the parathyroid glands. Recommendations for people with MEN2A include specialized screening for these tumors each year, consisting of blood work and ultrasound imaging.

At first, Cristi’s healthcare team thought her genetic results must be a mistake. This genetic finding was not consistent with her personal or family history. So, Cristi repeated the testing and confirmed that she definitely carried a RET variant. Another family member subsequently tested positive for the same variant.

Cristi’s healthcare team told her that she had up to a 95% chance to develop cancer. But because Cristi is a genetic counselor and has worked for several commercial laboratories, she dug deeper. Given her family history, which was not consistent with a traditional RET mutation, the results did not make sense to her. Cristi found a published paper in a medical journal showing that her specific RET variant is likely associated with a much lower risk of these cancers. Through her professional network, she obtained data from multiple laboratories on families with the same RET variant that appeared consistent with this journal article, and she scheduled an appointment with the article’s author. She even had a local genetic counselor and patient advocate attend her appointments virtually with the author to ensure that her local healthcare team would have the same information. Cristi was advised by the paper’s author that, in her case, screening for thyroid cancer would be a reasonable approach. Cristi decided to opt for regular blood screening and ultrasounds instead of surgical removal of her thyroid gland, which is the protocol for traditional RET variants. Cristi realized she was unique because most people with her initial testing result would not have access to these extraordinary resources and would have likely proceeded with removal of their thyroid gland, the approach her healthcare team and peers were recommending adamantly.

On its face, Cristi’s story seemed to be a success, although one driven by education, experience, and network. At first, she was understandably relieved. The treatment plan was non-invasive, reasonable, and data driven. Soon, however, Cristi learned that the plan was also financially toxic. We have published two previous papers discussing financial toxicity, including one in the setting of a breast cancer diagnosis.

Cristi had to wait 3 months for an appointment to see a specialist to have her screenings. Overall, the medical costs associated with establishing a screening plan that year and the associated health insurance deductibles cost her over $3,000. The average out-of-pocket costs in subsequent years for her RET specific screening are estimated to be at least $1,700/year, for the rest of her life - and that assumes additional testing is not necessary. If we include the costs she must pay for her at-risk breast cancer screenings, based on her family history, the total out-of-pocket comes to $3,200 a year. It is not surprising that many patients skip healthcare visits they need due to uncertainty around costs.

Ironically, the removal of Cristi’s thyroid gland – which was not necessarily warranted based on her genetic variant, would be covered by her health insurance, as would the lifetime medications needed post-removal, and time off for recovery. The facts beg the question: are patients being pushed to have organ and tissue removal, instead of surveillance, due to the costs of lifetime surveillance? We must answer this critical question before we can move forward with population genetic testing and precision medicine.

Now consider that Cristi’s children and other relatives are offered genetic testing based on her finding and, if positive, must also have undergo similar surveillance every year. If Cristi and/or her family members receive an abnormal, or even borderline testing result, they require more testing and imaging. These procedures may or may not be covered by their insurance given the lack of guidelines for mutations that do not confer the traditional risk.

Another issue to consider is that Cristi must use paid time off (PTO) for her, and her family members’, medical appointments. If we consider 10 days to be the average number of PTO for private sector employees who complete one year of service, this means that between her ‘RET’ visits, routine visits, dental and vision, Cristi will use 9.5 PTO days per year for preventative care. If we consider the average person’s PTO, that equals 9.5 out of 10 days off/year on medical appointments alone. This figure does not include routine appointments needed for her children, such as when they are sick, and of course it does not account for vacation time. This reality is the unfair price one person pays for doing what she can, and should, do to keep herself and her family healthy and cancer free.

Population testing may help people avoid serious diseases and death, which is a worthy goal for patients, employers, payers and our population at large. But if we support this testing, we must also support individuals who test positive for a pathogenic mutation by providing:

· accurate genetic counseling information from a specialist, tailored to that individual test result;

· updated information as we learn more about each genetic variant and recommended management;

· full coverage of both surveillance and prophylactic surgeries appropriate to that genetic finding;

· employer flexibility to support the PTO associated with the medical management pathways;

· clinics that support both high risk appointments and routine screening simultaneously, so that patients avoid multiple appointments at different sites spanning numerous days.

Population genetic testing is coming and will save lives and money, for our health care system and employers. But Cristi’s story is a cautionary tale: before we establish population testing programs, it is essential that we carve pathways for participants, to ensure that they are both covered and supported by their insurers, clinicians, and employers throughout this lifetime journey.

***Co-author Cristi Radford, MS, CGC is a genetic counselor who shifted her career to the payer space to develop programs addressing the unique needs of patients with genetic conditions. She is one of few professionals nationwide with expertise in genetic counseling and testing, the payer space, and financial toxicity.

Thu, 04 Aug 2022 05:00:00 -0500 Ellen Matloff en text/html https://www.forbes.com/sites/ellenmatloff/2022/08/04/population-genetic-testing-save-lives-and-money-while-avoiding-financial-toxicity/
Killexams : 8 Reasons Stress Testing Your Client’s Financial Plan Is So Important

While having a strong financial plan in place is crucial, stress testing that plan and assessing emergency risks is critical also, according to eMoney.

That is especially true in times like right now, when economic circumstances may be unstable amid inflation, continuing pandemic-related volatility and supply chain issues, financial planning experts at the Fidelity-owned company said Tuesday, during the webinar “5 Ways to Add Sizzle to Your Stress Tests.”

“With inflation and market volatility ever present and the potential for changes [in] taxes and more, it just might be the time to put your client’s plan through its paces and see how it would perform under a myriad of conditions,” Joseph Buhrmann, senior financial planning practice management consultant at eMoney Advisor, suggested at the start of the webinar.

“A financial plan is never a one-time event,” said Michelle Riiska, financial planning services consultant at eMoney Advisor. “To be effective, financial planning needs to be an ongoing process.”

Advisors need to help clients manage all areas of their financial lives and maintain dynamic plans that can absorb changes in the market, personal situations and priorities, she added.

In addition to stress testing client financial plans, Buhrmann suggested advisors evaluate their client experience and find more ways to engage digitally; elevate their reviews, focusing on holistic planning; and make sure to have a tech stack that helps enable engaging and scalable planning.

Take a look at the gallery above to see what he and Riiska cited as eight good reasons why stress testing financial plans is so important for advisors and their clients.

Wed, 27 Jul 2022 02:50:00 -0500 en text/html https://www.thinkadvisor.com/2022/07/27/8-reasons-stress-testing-your-clients-financial-plan-is-so-important/
Killexams : Natera Reports Second Quarter 2022 Financial Results

AUSTIN, Texas, Aug. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on accurate business progress and financial outlook.

(PRNewsfoto/Natera, Inc.)

Recent Accomplishments & Highlights

  • Generated total revenues of $198.2 million in the second quarter of 2022 compared to $142.0 million in the second quarter of 2021, an increase of 39.6%. Product revenues grew 39.3% over the same period.
  • Processed approximately 499,900 tests in the second quarter of 2022, compared to approximately 375,700 tests processed in second quarter of 2021, an increase of 33.0%.
  • 2022 revenue guidance raised to $805 million$825 million.
  • Selected to participate in UnitedHealthcare's Preferred Laboratory Network after a rigorous review process.
  • Publication of the Trifecta study for Prospera Kidney in Transplantation; largest prospective, multi-site, fully biopsy matched study to date.
  • Completed enrollment in RenaCARE study for Renasight, with more than 1,700 patients across 30+ sites.
  • Secured Medicare coverage for muscle invasive bladder cancer; fourth coverage decision for Signatera.
  • Presented substantial new Signatera data sets at the 2022 ASCO Annual Meeting.
  • Appointed Dr. Minetta Liu as CMO for Oncology.
  • Additional equity investment in Natera by Executive Chairman Matt Rabinowitz.

"Strong momentum driven by record volume levels enabled us to again raise our 2022 revenue guidance," said Steve Chapman, Natera's Chief Executive Officer. "We are proud to have served close to 500,000 patients in Q2. As we scale the business, we now see a clear path to reach a cash flow breakeven quarter by mid-2024. A key highlight in the quarter was receiving Medicare coverage for Signatera in muscle-invasive bladder cancer, representing the fourth coverage decision by Medicare for Signatera."

Second Quarter Ended June 30, 2022 Financial Results

Total revenues were $198.2 million in the second quarter of 2022 compared to $142.0 million for the second quarter of 2021, an increase of 39.6%. Product revenues were $194.6 million in the second quarter of 2022 compared to $139.6 million in the second quarter of 2021, an increase of 39.3%. The increase in product revenues was driven by an increase in test volumes compared to the second quarter of 2021. Natera processed approximately 499,900 tests in the second quarter of 2022, including approximately 484,000 tests accessioned in its laboratory, compared to approximately 375,700 tests processed, including approximately 361,500 tests accessioned in its laboratory, in the second quarter of 2021, an increase of 33.1% for the quarter.

In the three months ended June 30, 2022, Natera recognized revenue on approximately 461,300 tests for which results were reported to customers in the period (tests reported), including approximately 446,400 tests reported from its laboratory, compared to approximately 355,700 tests reported, including approximately 342,500 tests reported from its laboratory, in the second quarter of 2021, an overall increase of 29.7% for the quarter.

Gross profit* for the three months ended June 30, 2022 and 2021 was $89.0 million and $65.9 million, respectively, representing a gross margin of 44.9% and 46.4%, respectively. Natera had lower margins in the second quarter of 2022 compared to the second quarter of 2021 primarily due to increased labor and overhead costs driven by volume growth and product support.

Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the second quarter of 2022 were $232.0 million, compared to $181.2 million in the same period of the prior year, an increase of 28.0%. The increases were primarily driven by headcount growth to support the Company's expansion, volume growth, and product development.

Loss from operations for the second quarter of 2022 was $143.1 million compared to $115.3 million for the same period of the prior year.

Net loss for the second quarter of 2022 was $145.2 million, or ($1.50) per diluted share, compared to net loss of $116.0 million, or ($1.32) per diluted share, for the same period in 2021. Weighted average shares outstanding were approximately 96.6 million in the second quarter of 2022 compared to 88.1 million in the second quarter of the prior year.

At June 30, 2022, Natera held approximately $638.7 million in cash, cash equivalents, short-term investments and restricted cash, compared to $914.5 million as of December 31, 2021. As of June 30, 2022, Natera had a total outstanding debt balance of $331.1 million, comprised of $50.1 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day LIBOR plus 110 bps and a net carrying amount of $281.0 million under its seven-year convertible senior notes. The convertible senior notes were issued in April 2020 for net proceeds of $278.3 million. The gross principal balance outstanding for the convertible senior notes was $287.5 million as of June 30, 2022.

Financial Outlook

Natera anticipates 2022 total revenue of $805 million to $825 million; 2022 gross margin to be approximately 46% to 48% of revenues; selling, general and administrative costs to be approximately $560 million to $590 million; research and development costs to be $340 million to $360 million, and net cash consumption to be $370 million to $400 million**.

* Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.

** Cash consumption is calculated as the sum of GAAP net cash used by operating activities (estimated for 2022 to be between $370 million and $400 million) and GAAP net purchases of property and equipment (estimated for 2022 to be approximately $60 million).

Test Volume Summary
Unit Q2 2022 Q2 2021 Definition
Tests processed 499,900 375,700 Tests accessioned in our laboratory plus units processed outside of our laboratory
Tests accessioned 484,000 361,500 Test accessioned in our laboratory
Tests reported in our laboratory 446,400 342,500 Total tests reported in our laboratory less units reported outside of our laboratory

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Conference Call Information

Event:                  Natera's Second Quarter 2022 Financial Results Conference Call
Date:  Thursday
Time:  1:30 p.m. PT (4:30 p.m. ET)
Registration Link: https://register.vevent.com/register/BIe5f2760824684a6ba2abc45faf3aa41e

To access the call, please register using the link above. You will then receive dial-in details and a unique PIN needed to join the call.

Forward-Looking Statements

This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995.  All statements other than statements of historical facts, including the company's financial guidance for fiscal 2022, its ability to continue to increase its revenues, its product development plans and its ability to maintain and grow its business operations in light of the COVID-19 pandemic, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera's current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to maintain our business and operations as planned due to disruptions and economic uncertainty caused by the COVID-19 pandemic; we may be unable to further increase the use and adoption of Panorama and Horizon through our direct sales efforts or through our laboratory partners; we may be unable to develop and successfully commercialize new products, including Signatera and Prospera; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; we may need to raise additional capital to support our business plans, which may not be available when necessary or on favorable terms; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly in the average-risk pregnancy population or for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratory facilities becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors, such as the increased focus by third-party payers on requiring that prior authorization be obtained prior to conducting a test; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, resulting from either third party claims of intellectual property infringement or third party infringement of our technology, is costly, time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot certain that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes.

Additional risks and uncertainties that could affect our financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most accurate filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC's website at www.sec.gov.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.

Contacts

Natera, Inc.

Investor Relations
Mike Brophy, CFO, Natera, Inc., 510-826-2350

Media 
Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com

 

Natera, Inc.
Consolidated Balance Sheets
(in thousands, except par value)
June 30,  December 31, 
2022 2021
(Unaudited) (1)
Assets
Current assets:
Cash and cash equivalents $ 91,298 $ 84,386
Restricted cash 86 228
Short-term investments 547,353 829,896
Accounts receivable, net of allowance of $3,561 in 2022 and $2,429 in 2021 208,312 122,074
Inventory 30,465 26,909
Prepaid expenses and other current assets, net 24,041 29,645
Total current assets 901,555 1,093,138
Property and equipment, net 81,772 65,516
Operating lease right-of-use assets 62,147 59,013
Other assets 21,502 18,820
Total assets $ 1,066,976 $ 1,236,487
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 28,192 $ 27,206
Accrued compensation 32,959 40,941
Other accrued liabilities 124,372 93,353
Deferred revenue, current portion 16,009 7,404
Short-term debt financing 50,086 50,052
Total current liabilities 251,618 218,956
Long-term debt financing 281,020 280,394
Deferred revenue, long-term portion 20,721 21,318
Operating lease liabilities, long-term portion 65,417 61,036
Other long-term liabilities 3,618 1,479
Total liabilities 622,394 583,183
Commitments and contingencies
Stockholders' equity:
Common stock 10 10
Additional paid in capital 2,139,551 2,050,417
Accumulated deficit (1,678,582) (1,394,836)
Accumulated other comprehensive loss (16,397) (2,287)
Total stockholders' equity 444,582 653,304
Total liabilities and stockholders' equity $ 1,066,976 $ 1,236,487
(1) The consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.
(2) As of June 30, 2022 and December 31, 2021, there were approximately 96,903,000 and 95,140,000 shares of common stock issued and outstanding, respectively.

 

Natera, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
Three months ended Six months ended
June 30,  June 30, 
2022 2021 2022 2021
(Unaudited) (1) (Unaudited) (1)
Revenues
Product revenues $ 194,582 $ 139,647 $ 384,584 $ 260,031
Licensing and other revenues 3,618 2,379 7,749 34,311
Total revenues 198,200 142,026 392,333 294,342
Cost and expenses
Cost of product revenues 108,756 75,527 211,426 141,359
Cost of licensing and other revenues 481 585 1,026 1,566
Research and development 82,580 53,752 162,994 93,940
Selling, general and administrative 149,468 127,456 297,102 235,788
Total cost and expenses 341,285 257,320 672,548 472,653
Loss from operations (143,085) (115,294) (280,215) (178,311)
Interest expense (2,150) (2,075) (4,237) (4,148)
Interest and other income, net 277 1,585 1,078 2,956
Loss before income taxes (144,958) (115,784) (283,374) (179,503)
Income tax expense (193) (242) (372) (376)
Net loss $ (145,151) $ (116,026) $ (283,746) $ (179,879)
Unrealized loss on available-for-sale securities, net of tax (2,493) (756) (14,110) (1,818)
Comprehensive loss $ (147,644) $ (116,782) $ (297,856) $ (181,697)
Net loss per share:
Basic and diluted $ (1.50) $ (1.32) $ (2.95) $ (2.06)
Weighted-average number of shares used in computing
Basic and diluted 96,579 88,077 96,081 87,387
(1) The condensed, consolidated Statements of Operations and Comprehensive Loss for the year ended December 31, 2021 have been derived from the audited consolidated financial statements for the periods included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

Cision View original content to get multimedia:https://www.prnewswire.com/news-releases/natera-reports-second-quarter-2022-financial-results-301600418.html

SOURCE Natera, Inc.

Thu, 04 Aug 2022 08:11:00 -0500 en text/html https://markets.businessinsider.com/news/stocks/natera-reports-second-quarter-2022-financial-results-1031652436
Killexams : A wake-up call: Your financial plan can help 'stress test' your retirement strategy through inflation, market downturn

Connie Gores was in her mid-50s, with one daughter in college and another newly graduated, when she became keenly focused on preparing for retirement. 

Gores, who worked in higher education and was a college president, met with a financial advisor set up by her former employer during the financial crisis of 2008. "The conversation changed my life," she recalled from her North Carolina home. 

She asked the advisor to project what her financial life in retirement would look like with the benefits and savings she had at the time. "He said to me, 'Well, I just want to tell you that right now, as it sits, you will not have enough money to live the way you want to live, and you'll have basically Social Security and a little more." 

More from Your Money Your Future:

Here's a look at more stories on how to manage, grow and protect your money for the years ahead.

It was a wake-up call, Gores said. 

Her mother had worked in hourly jobs until she was 82, got sick and died three months later. "That is not the life I wanted," Gores said. "I wanted to have a different kind of actual retirement."

North Carolina retiree Connie Gores prepares for a visit with her grandchildren.

CNBC Jerry Frasier

She and her advisor talked about different strategies and came up with a plan to save and invest her money. She started contributing the maximum to her workplace retirement plan and to a Roth IRA. She stuck with the plan, reviewing it annually over the next decade, and was able to retire at 65 — several years earlier than she had expected. 

You can't just assume that 'I'm just gonna just keep putting money aside into my retirement account and see the value go up every year.'

Shelly Ann Eweka

senior director of financial planning strategy at TIAA

"Staying the course" is often cited as a key retirement savings strategy by financial advisors. Yet, that can be tough for many workers as they try to stomach a dramatic plunge in the stock market. The S&P 500 Index, for example, lost 20% in the first six months of this year, the worst mid-year performance in over a half a century. 

"It is hard emotionally when you go online and you see your account value just dropping, dropping, dropping, but I encourage everybody to stay focused," said Shelly-Ann Eweka, a certified financial planner and the senior director of financial planning strategy at TIAA.

Be sure to 'stress test' your strategy

How to make a financial plan

Carol Yepes | Moment | Getty Images

To get started making a financial plan for retirement, advisors say you need to:

  • Understand your expenses and your needs and wants in retirement. 
  • Estimate what income you'll receive from pension, Social Security, investments and any part-time or other income. 
  • Factor in future health-care costs, as well. 

"It's really important for people to know what those costs are — to see how much they need to allocate to health care so that they can truly maintain their standard of living," said Ron Mastrogiovanni, president and CEO of HealthView Services.

Gores, now 68, has taken those steps and is sticking to her financial plan. She believes she will be able to continue to live comfortably in retirement while earning some extra income from executive coaching, consulting and teaching part-time. 

She also now has time to travel and spend time with her grandchildren. "I still have a purpose and to my profession, and I also can be this nanna that is in their lives," she said.

Tue, 19 Jul 2022 07:31:00 -0500 en text/html https://www.cnbc.com/2022/07/19/how-to-stress-test-retirement-strategy-amid-inflation-market-downturn.html
Killexams : Why inspection & certification for cybersecurity testing is a must for manufacturing businesses
 Sandip Kumar Panda, CEO, Co-founder, InstaSafe
Sandip Kumar Panda, CEO, Co-founder, InstaSafe

One of the biggest cybersecurity threats in the manufacturing industry is supply chain attacks. Manufacturing entities are always interdependent with a lot of suppliers, logistics partners and other supply chain partners for their production.

With so much interdependence, their applications are highly vulnerable to cyber attacks. If one of the third party systems gets breached, it can affect the main manufacturing entity.

To mitigate this, there needs to be proper remote access provisions for third party consultants to secure access ERP applications with enhanced multi factor authentication. There is a bigger scope of cybersecurity testing of this wide spread and inter connected infrastructure of manufacturing organizations.

Today, manufacturing facilities have large production units that run on an automated mechanism, wherein very little human intelligence is required after the software receives directions for operations. It is no debate that in case of a halt in production owing to software malfunction, even for a day, it incurs substantial financial losses alongside downplaying the reputation of a manufacturing plant.

The background of these developments makes it essential for quality-quantity operational units pre-set in the software to have space for zero malfunction. In addition, it also brings forth the necessity to ensure software's smooth running and assurance to the company that the software is at par with the standards it seeks. Certification plays a pivotal role here and guarantees the level of trust a company can put up in the software's work.

Certification of cybersecurity technology is crucial to creating in-depth knowledge of the possible threats in the virtual world. It showcases a code of conduct and ethics for an employer to hire. For an academic learner, it gives an added advantage and better understanding of the university or a course a student would be pursuing or might have followed in the past.

There are primarily two types of programs for certification – professional cybersecurity certifications for individuals working in the cybersecurity field that are looking at enhancing their skills with the latest tools and software. The course is primarily an upskilling certification to upgrade your learnings in the ever-changing cybersecurity landscape. The other program is the academic cybersecurity landscape – curated for students to provide an in-depth understanding of possible threats with which software can be targeted to analyze different aspects of cybersecurity.

In addition to knowledge sharing, certification in information technology courses specifically curated to enhance knowledge in cybersecurity and in-hand experience of dealing with large machines cumulatively also helps an employee become a professional inspection officer.

These individuals play a primary role in the functioning of a manufacturing unit, especially under the crisis inspection checks that help manufacturing units dodge a potential crisis. They also validate the reasoning behind malfunctions and guide the operators to quick functioning and stabilize the workforce management in the production unit.

Integrated technology fosters increased data collection

Integrated production lines using smart sensors and actuators to collect data digitally has driven more flexible production and increased the rapid adoption of new technologies over the past decade.

The desire for increased data collection continues to gain momentum and has spread across processing and packaging operations, with most companies moving toward an IIoT model of manufacturing.

This is beyond automated machine functionality and towards integrated machine communications, adopting digital data exchange.

Assessing a Cloud Service Provider

With manufacturing firms hosting their workloads in a cloud environment, it’s important for CISOs to correctly assess the capabilities of their Cloud Service Providers (CSPs). There are several factors CISOs can use to assess their CSPs, for instance:

  • If the update and patching of systems is carried out regularly
  • Do they have a dedicated team following Verified best practices or standards to detect and remediate breaches
  • Testing their teams’ cybersecurity preparedness on a regular basis with mock intrusions
  • Maintaining a robust information security system

IoT testing imperative to prevent cyberattacks

With the growing implementations of
Industrial Internet of Things (IIoT) applications and services, the spectrum of cybersecurity threats has changed with it and requires enhanced security measures and controls to be developed. The threats and types of breaches possible on the internet during the pandemic must not be underestimated.

Breaches happening in the industrial IoT domain would be critical due to specific exposures that are related to machine-to-machine communication and environments, these M2M communication networks are an integral part of connected factories involving high dependency on next generation wireless communication systems (5G, time sensitive networking, etc.) and involving self-automated, self-driven, and self-learning network characteristics.

Though IoT device manufacturers are heavily investing in the development of new solutions, these organizations often lack the security expertise and the technical resources to ensure that high levels of security are built into their products.

(This article is authored by Sandip Kumar Panda, CEO & Co-founder of InstaSafe Technologies)

Fri, 22 Jul 2022 00:29:00 -0500 en text/html https://cio.economictimes.indiatimes.com/news/digital-security/why-inspection-certification-for-cybersecurity-testing-is-a-must-for-manufacturing-businesses/93044153 Killexams : State Department Awards $350M Financial Management Support Contract to IFAS

Woodbridge, Virginia-based Integrated Finance and Accounting Solutions has been awarded a potential $350 million contract to provide support services to the State Department’s Bureau of the Comptroller and Global Financial Services.

The department announced the Charleston Global Financial Services indefinite-delivery/ indefinite-quantity contract through an award notice published Friday.

CGFS-Charleston provides financial services to the State Department, including domestic organizations and posts abroad.

Under the IDIQ contract, the contractor will provide certified and trained financial and information technology professionals and administrative services staff in support of the department’s basic financial accounting, disbursement and payroll functions for foreign service officers, civil service personnel and local employees supporting the department’s overseas posts.

The vendor will also deliver related support services, including financial systems analysis, design; business process analysis; testing; implementation support; database management; system integration and operations support; configuration management; technical and operational analysis; enterprise resource analysis and processing; help desk; security; accounting services; budgeting; financial reporting and analysis; audit follow-up services; planning and performance measurement services; reconciliation; and training, according to the scope of work.

Sun, 07 Aug 2022 22:05:00 -0500 en-US text/html https://www.govconwire.com/2022/08/state-department-awards-350m-financial-services-contract-to-ifas/
Killexams : Breaking News: Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics

Todos Medical, Ltd. (OTCQB: TOMDF)a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based MonkeyPox testing. Under the plan, the Company is validating multiple PCR assays for MonkeyPox and will launch the most sensitive for lesion-based and saliva-based trial collections. While lesion-based testing is the current standard of care according to CDC guidelines, saliva-based trial collection is currently undergoing intense research that could open up the potential for testing of asymptomatic or very early-stage patients at high risk of severe disease (such as immunocompromised patients) that could result in earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat (TPOXX). TPOXX is an investigational drug candidate, and currently only available under an expanded access Investigational New Drug (EA-IND) protocol. The MonkeyPox tests are being developed as Laboratory Developed Tests (LDTs). A accurate peer-reviewed article describing strong correlation of the sensitivity of lesion and saliva-based PCR testing was recently published in the journal Eurosurveillance: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.28.2200503

“The significant investment we made to automate PCR testing at Provista to maximize COVID testing capacity can now be partially redeployed towards MonkeyPox as we prepare to help the nation scale-up MonkeyPox testing capacity to meet the emerging public health crisis,” said Gerald E. Commissiong, President & CEO of Todos Medical.

About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel, and Provista’s proprietary commercial-stage Videssa® breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitor botanical and pharmaceutical products that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid® in the United States, is developing the dual mechanism 3CL protease inhibitor & anti-cytokine therapeutic drug candidate Tollovir®, while also developing the 3CL protease inhibitor diagnostic TolloTest™.

Sponsored Content Release. Click for Full Disclosure

Wed, 03 Aug 2022 01:59:00 -0500 text/html https://www.financialbuzz.com/breaking-news-todos-medical-initiates-validation-plan-for-pcr-based-monkeypox-test-at-clia-cap-clinical-testing-laboratory-provista-diagnostics/
Killexams : Highlights from the Ratings and Financial Report for Heart Test Laboratories Inc. (HSCS)

Heart Test Laboratories Inc. (NASDAQ:HSCS) went up by 89.60% from its latest closing price compared to the accurate 1-year high of $3.75. The company’s stock price has collected 134.29% of gains in the last five trading sessions.

Is It Worth Investing in Heart Test Laboratories Inc. (NASDAQ :HSCS) Right Now?

Opinions of the stock are interesting as 0 analysts out of 0 who provided ratings for Heart Test Laboratories Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

HSCS currently public float of 5.32M and currently shorts hold a 0.50% ratio of that float. Today, the average trading volume of HSCS was 251.34K shares.

HSCS’s Market Performance

The volatility ratio for the week stands at 69.50% while the volatility levels for the past 30 days are set at 25.45% for Heart Test Laboratories Inc. The simple moving average for the period of the last 20 days is 126.27% for HSCS stocks with a simple moving average of 101.07% for the last 200 days.

HSCS Trading at 101.07% from the 50-Day Moving Average

After a stumble in the market that brought HSCS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.53% of loss for the given period.

Volatility was left at 25.45%, however, over the last 30 days, the volatility rate increased by 69.50%, as shares surge +89.60% for the moving average over the last 20 days.

During the last 5 trading sessions, HSCS rose by +134.29%, in comparison to the 20-day moving average, which settled at $1.5300. In addition, Heart Test Laboratories Inc. saw 92.94% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for HSCS

Current profitability levels for the company are sitting at:

  • -10030.18 for the present operating margin
  • -72.93 for the gross margin

The net margin for Heart Test Laboratories Inc. stands at -9577.29.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.31.

Wed, 03 Aug 2022 19:20:00 -0500 en-US text/html https://newsheater.com/2022/08/04/highlights-from-the-ratings-and-financial-report-for-heart-test-laboratories-inc-hscs/
Killexams : “Buzz on the Street” Show: Todos Medical (OTCQB: TOMDF) Validation Plan for MonkeyPox Test

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics.”

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based MonkeyPox testing. Under the plan, the Company is validating multiple PCR assays for MonkeyPox and will launch the most sensitive for lesion-based and saliva-based trial collections. While lesion-based testing is the current standard of care according to CDC guidelines, saliva-based trial collection is currently undergoing intense research that could open up the potential for testing of asymptomatic or very early-stage patients at high risk of severe disease (such as immunocompromised patients) that could result in earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat (TPOXX). TPOXX is an investigational drug candidate, and currently only available under an expanded access Investigational New Drug (EA-IND) protocol. The MonkeyPox tests are being developed as Laboratory Developed Tests (LDTs).

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.

For more information, please visit: Todos Medical Ltd.

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

Wed, 03 Aug 2022 08:09:00 -0500 text/html https://www.financialbuzz.com/buzz-on-the-street-show-todos-medical-otcqb-tomdf-validation-plan-for-monkeypox-test/
CIA-I exam dump and training guide direct download
Training Exams List